Unilateral Ptosis and Bulbar Symptoms as the Initial Presentation of Late-Onset Acetylcholine Receptor Antibody-Positive Myasthenia Gravis Mimicking Acute Ischemic Stroke in an 82-Year-Old Man - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41573440/
Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. In older adults, it may present with bulbar and ocular symptoms that resemble acute stroke. Ocular myasthenia is typically asymmetric...
Case report describes late onset acetylcholine receptor antibody positive myasthenia gravis presenting with unilateral ptosis and fluctuating bulbar symptoms mimicking stroke, highlighting diagnostic pitfalls and importance of fatigability assessment clinical.
Health Literacy in Patients With Myasthenia Gravis: A Cross-Sectional Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41527741/
Symptom-burdened patients and centres without specialized nursing support appear to be priority targets for HL-oriented interventions and organizational redesign.
Cross-sectional Italian study finds problematic health literacy in adults with myasthenia gravis, with lower scores linked to symptom burden and improved domains associated with specialized nursing support in neurology centers.
Health Literacy in Patients With Myasthenia Gravis: A Cross-Sectional Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41527741/
Symptom-burdened patients and centres without specialized nursing support appear to be priority targets for HL-oriented interventions and organizational redesign.
Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41517964/
The ADAPT trial is registered on ClinicalTrials.gov (NCT03669588).
Post hoc ADAPT trial analysis shows comparable efficacy, safety, and quality-of-life improvements with efgartigimod in female and male AChR-antibody–positive generalized myasthenia gravis patients, supporting sex-equitable treatment response.
BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41481736/
Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for...
Study demonstrates BCMA/CD19 CAR T cell therapy induces durable, drug-free remission in refractory myasthenia gravis, with B-cell reconstitution patterns, proteomic shifts, and FCRL5 identified as a potential relapse biomarker.